Ann Allen

1.1k total citations
45 papers, 873 citations indexed

About

Ann Allen is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Pharmacology. According to data from OpenAlex, Ann Allen has authored 45 papers receiving a total of 873 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Physiology, 24 papers in Pulmonary and Respiratory Medicine and 8 papers in Pharmacology. Recurrent topics in Ann Allen's work include Asthma and respiratory diseases (26 papers), Inhalation and Respiratory Drug Delivery (18 papers) and Respiratory and Cough-Related Research (9 papers). Ann Allen is often cited by papers focused on Asthma and respiratory diseases (26 papers), Inhalation and Respiratory Drug Delivery (18 papers) and Respiratory and Cough-Related Research (9 papers). Ann Allen collaborates with scholars based in United Kingdom, United States and Germany. Ann Allen's co-authors include Rodger Kempsford, Philippe Bareille, Jesper Hallas, Søren H. Sindrup, Graham Allen, Lars F. Gram, G. Mellows, Barry D. Zussman, Erik Skjelbo and Kim Brøsen and has published in prestigious journals such as Journal of Clinical Oncology, Antimicrobial Agents and Chemotherapy and European Respiratory Journal.

In The Last Decade

Ann Allen

45 papers receiving 828 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ann Allen United Kingdom 17 396 377 233 148 109 45 873
Keita Hirai Japan 16 199 0.5× 218 0.6× 115 0.5× 55 0.4× 85 0.8× 50 690
A. Grahnén Sweden 17 133 0.3× 137 0.4× 164 0.7× 79 0.5× 31 0.3× 40 756
Jeffrey W. Dubb United States 11 147 0.4× 143 0.4× 133 0.6× 51 0.3× 43 0.4× 17 626
Robert L. Kunka United States 14 99 0.3× 131 0.3× 92 0.4× 26 0.2× 41 0.4× 20 468
Mitsutaka Kanamaru Japan 15 71 0.2× 56 0.1× 187 0.8× 44 0.3× 90 0.8× 44 698
M Zschiesche Germany 12 69 0.2× 165 0.4× 90 0.4× 190 1.3× 59 0.5× 44 764
Thomas D. Bell United States 10 232 0.6× 316 0.8× 112 0.5× 110 0.7× 96 0.9× 14 631
Vijay O. Bhargava United States 15 33 0.1× 46 0.1× 155 0.7× 96 0.6× 108 1.0× 35 480
Robert M. Stote United States 14 118 0.3× 40 0.1× 130 0.6× 61 0.4× 48 0.4× 25 702
Angelo Tesoro Canada 9 82 0.2× 42 0.1× 144 0.6× 51 0.3× 54 0.5× 21 380

Countries citing papers authored by Ann Allen

Since Specialization
Citations

This map shows the geographic impact of Ann Allen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann Allen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann Allen more than expected).

Fields of papers citing papers by Ann Allen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann Allen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann Allen. The network helps show where Ann Allen may publish in the future.

Co-authorship network of co-authors of Ann Allen

This figure shows the co-authorship network connecting the top 25 collaborators of Ann Allen. A scholar is included among the top collaborators of Ann Allen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann Allen. Ann Allen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Allen, Ann, Robert Murdoch, Philippe Bareille, et al.. (2015). Pharmacokinetics, Safety, and Tolerability of Once‐Daily Intranasal Fluticasone Furoate and Levocabastine Administered Alone or Simultaneously as fluticasone Furoate/Levocabastine Fixed‐Dose Combination. Clinical Pharmacology in Drug Development. 5(3). 225–231. 1 indexed citations
2.
Siederer, Sarah, Ann Allen, & Shuying Yang. (2015). Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease. European Journal of Drug Metabolism and Pharmacokinetics. 41(6). 743–758. 9 indexed citations
3.
Brealey, Noushin, et al.. (2015). Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics. 53(9). 753–764. 17 indexed citations
4.
Oliver, Amanda J., et al.. (2014). Tolerability of Fluticasone Furoate/Vilanterol Combination Therapy in Children Aged 5 to 11 Years With Persistent Asthma. Clinical Therapeutics. 36(6). 928–939.e1. 15 indexed citations
5.
Shapiro, Geoffrey I., Mark R. Middleton, Howard A. Burris, et al.. (2013). Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 12. 3 indexed citations
6.
Allen, Ann. (2013). The Relationship Between Fluticasone Furoate Systemic Exposure and Cortisol Suppression. Clinical Pharmacokinetics. 52(10). 885–896. 26 indexed citations
7.
Kempsford, Rodger, et al.. (2013). The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. International Journal of Clinical Pharmacology and Therapeutics. 51(8). 660–671. 14 indexed citations
8.
9.
Allen, Ann, Angela Davis, Kelly Hardes, Lee Tombs, & Rodger Kempsford. (2012). Influence of Renal and Hepatic Impairment on the Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Fluticasone Furoate and Vilanterol in Combination. Clinical Therapeutics. 34(12). 2316–2332. 17 indexed citations
10.
Kempsford, Rodger, et al.. (2012). The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects. British Journal of Clinical Pharmacology. 75(6). 1478–1487. 23 indexed citations
11.
Kempsford, Rodger, et al.. (2011). The safety, tolerability, pharmacodynamics and pharmacokinetics of inhaled fluticasone furoate (FF) and vilanterol (VI) are unaffected by administration in combination. European Respiratory Journal. 38(Suppl 55). p824–p824. 13 indexed citations
12.
Shardlow, P. C., et al.. (2008). Metabolism and Disposition of Fluticasone Furoate, an Enhanced-Affinity Glucocorticoid, in Humans. Drug Metabolism and Disposition. 36(11). 2337–2344. 32 indexed citations
13.
Allen, Ann, et al.. (2007). Absolute Bioavailability of Intranasal Fluticasone Furoate in Healthy Subjects. Clinical Therapeutics. 29(7). 1415–1420. 39 indexed citations
14.
Allen, Ann, et al.. (1999). Lack of Pharmacokinetic Interaction between Gemifloxacin and Digoxin in Healthy Elderly Volunteers. Chemotherapy. 45(6). 485–490. 12 indexed citations
15.
Allen, Ann, et al.. (1999). Effect of Omeprazole on the Pharmacokinetics of Oral Gemifloxacin in Healthy Volunteers. Chemotherapy. 45(6). 496–503. 18 indexed citations
16.
Ferguson, James, et al.. (1999). Evaluation of Phototoxic Potential of Gemifloxacin in Healthy Volunteers Compared with Ciprofloxacin. Chemotherapy. 45(6). 512–520. 31 indexed citations
17.
Allen, Ann, et al.. (1999). Lack of Effect of Gemifloxacin on the Steady-State Pharmacokinetics of Theophylline in Healthy Volunteers. Chemotherapy. 45(6). 478–484. 16 indexed citations
18.
Allen, Ann, et al.. (1999). Effect of Maalox<sup>®</sup> on the Bioavailability of Oral Gemifloxacin in Healthy Volunteers. Chemotherapy. 45(6). 504–511. 22 indexed citations
19.
Cupissol, Didier, James Carmichael, E.M. Bessell, et al.. (1993). Evaluation of the Bioequivalence of Tablet and Capsule Formulations of Granisetron in Patients Undergoing Cytotoxic Chemotherapy for Malignant Disease. Journal of Pharmaceutical Sciences. 82(12). 1281–1284. 14 indexed citations
20.
Sindrup, Søren H., Kim Brøsen, Lars F. Gram, et al.. (1992). The relationship between paroxetine and the sparteine oxidation polymorphism. Clinical Pharmacology & Therapeutics. 51(3). 278–287. 173 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Keita Hirai Breakdown of academic impact, for papers by A. Grahnén Breakdown of academic impact, for papers by Jeffrey W. Dubb Breakdown of academic impact, for papers by Robert L. Kunka Breakdown of academic impact, for papers by Mitsutaka Kanamaru Breakdown of academic impact, for papers by M Zschiesche Breakdown of academic impact, for papers by Thomas D. Bell Breakdown of academic impact, for papers by Vijay O. Bhargava Breakdown of academic impact, for papers by Robert M. Stote Breakdown of academic impact, for papers by Angelo Tesoro
Rankless by CCL
2026